On August 9^th, the General Office of the National Health Commission and the Office of the National Administration of Traditional Chinese Medicine issued the "Notice on Including Azvudine Tablets in the Diagnosis and Treatment Plan of COVID-19".

The Notice noted that the drug has been included in the "COVID-19 Diagnosis and Treatment Plan (Ninth Edition)" according to the National Medical Products Administration’s conditional approval of the registration application for the increasing indications for the treatment of COVID-19 of Azvudine tablets.